Physician profile
Daniel Pina
NPI 1720479884
$5,905.43
in general payments reported to CMS, 2019-2025
26 companies · $944 in 2025
The $944 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,074 · 2022: $1,537 · 2023: $1,508 · 2024: $842 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,294.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,070.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $469.85 | 2021-2025 | |
| Lilly USA, LLC | $466.55 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $458.82 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Optinose US, INC. | $433.63 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.97 | 2021-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.69 | 2021-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $381.20 | 2021-2025 | Farxiga, Airsupra |
| Ironwood Pharmaceuticals, INC | $315.34 | 2021-2025 | Linzess |
| Otsuka America Pharmaceutical, INC. | $299.62 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $263.87 | 2021-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $151.09 | 2021-2023 | Xarelto |
| Amarin Pharma, INC. | $147.71 | 2021-2022 | |
| Abbott Laboratories | $109.56 | 2023-2025 | Proclaim, Freestyle Libre, Freestyle Libre 3 |
| Amgen INC. | $99.80 | 2021-2024 | Krystexxa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $70.61 | 2022-2025 | |
| Ardelyx, INC. | $69.18 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $64.76 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $55.47 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $55.21 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $54.29 | 2021-2022 | |
| Redhill Biopharma INC. | $24.20 | 2021 | |
| Dexcom, INC. | $16.62 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $16.18 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.00 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.